Thomas Olin was born in 1958 and is the CEO. Ph.D. in physiology and M.Sc. in biology, chemistry and geosciences. Olin has more than 20 years' experience of both scientific and business management from biotechnology and pharmaceutical companies. He was part of the management group that led the hiving off of Biovitrum from Pharmacia and was later part of the research and business development management at Biovitrum. Olin was responsible for the hiving off of iNovacia from Biovitrum in 2006. He also has extensive experience of the licensing of pharmaceutical development projects.
Shareholding: 1,802,512 shares.

    Martin Norin, COO was born in 1959. Ph.D. in biochemistry and M.Sc. in chemistry from the KTH Royal Institute of Technology in Stockholm. Norin has long experience of working in pharmaceutical research. Among other things, he has been a project manager and member of the committee for pharmaceutical development in the preclinical phase at Pharmacia and Biovitrum. Along with  Thomas Olin, he led the spin-off of iNovacia from Biovitrum in 2006. As the person in charge of chemistry at Biovitrum AB, Norin was responsible for more than 70 scientists.
Shareholding: 33,559 shares.


Copyright 2010 KANCERA AB, KAROLINSKA INSTITUTET SCIENCE PARK, BANVAKTSVÄGEN 22, 171 48 SOLNA. TEL: +46 (0)850 12 60 80 Website policy